OptiNose股票討論區

$OptiNose(OPTN.US)$ 07:02 AM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M
OptiNose Q1 EPS USD -0.12 Vs. Ibes Estimate USD -0.11
Optinose Sees 2024 XHANCE Revenue in $85M to $95M Range >OPTN

$OptiNose(OPTN.US)$
NEWS
Optinose Announces $55 Million Registered Direct Offering

$Processa Pharmaceuticals(PCSA.US)$ $Barfresh Food(BRFH.US)$ $Intelligent Living Application(ILAG.US)$ $SuperCom(SPCB.US)$ $reAlpha Tech(AIRE.US)$ $OptiNose(OPTN.US)$
📊⚡️📊

$OptiNose(OPTN.US)$ SOPTN XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal
Polyps

$OptiNose(OPTN.US)$ Approved 🚀🚀🚀🚀

Last week’s PDUFAs:
$百濟神州(BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$施貴寶(BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ®  + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$萬達生物製藥(VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ® 
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia(EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...

$OptiNose(OPTN.US)$ OptiNose (NASDAQ:OPTN) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 47.06 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $19.86 million which beat the analyst consensus estimate of $19.23 million by 3.30 percent. This is a 4.75 percent decrease over sales of $20.86 million the same period last year.